FMP
Catabasis Pharmaceuticals, Inc.
CATB
NASDAQ
Inactive Equity
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.
8.54 USD
-0.64000034 (-7.49%)
Historical Prices
From:
To:
About
Description
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research In...
CIK
0001454789
ISIN
US14875P2065
CUSIP
14875P206
Address
100 High Street, 28th Floor
Phone
16173491971
Country
US
Employee
20
IPO Date
Jun 25, 2015
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
CATB Financial Summary
CIK
0001454789
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
14875P206
ISIN
US14875P2065
Country
US
Price
8.54
Beta
1.66
Volume Avg.
528.92k
Market Cap
234.86M
Shares
-
52-Week
8.48-9.21
DCF
16.12
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
0
P/B
-
Website
http://www.catabasis.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CATB News
Benzinga
Sep 8, 2021
Catabasis Renames As Astria Therapeutics With New Disease Fo...
Once-struggling, Catabasis Pharmaceuticals Inc (NASDAQ: CATB) is looking to hit the reset button with a new name and focus. Catabasis has been dragging for several years, weighed down mainly by the failure of the edasalonexent program in Duchenne muscular dystrophy.
Pulse2
Aug 20, 2021
Catabasis Pharmaceuticals Shares: 1-For-6 Split Goes Into Ef...
Catabasis Pharmaceuticals Inc (NASDAQ: CATB) deployed a reverse stock split of its shares of common stock at a ratio of 1-for-6. These are the details.
Seeking Alpha
Jun 30, 2021
Catabasis Pharmaceuticals: Transformation Through Quellis Bi...
Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
Pulse2
Jun 16, 2021
CATB Stock Price Increases Over 40% Pre-Market: Why It Happe...
The stock price of Catabasis Pharmaceuticals Inc (NASDAQ: CATB) increased by over 40% pre-market. This is why it happened.
Business Wire
May 14, 2021
Catabasis Pharmaceuticals To Present At Upcoming Investor Co...
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
Business Wire
Mar 11, 2021
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Ye...
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
24/7 Wall Street
Mar 11, 2021
AEP, Oracle, Tesla and More Thursday Afternoon Analyst Calls
With the trading day halfway over, the broad markets were making yet another strong push.
Business Wire
Mar 2, 2021
Catabasis Pharmaceuticals To Present At Upcoming Investor Co...
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences.
